The Ethics of Extending Life: Who Actually Gets to Live Longer?

Longevity science tends to get discussed in almost purely technical terms: which supplement, which biomarker, which protocol. A recent piece in the Journal of Medical Internet Research, written by correspondent Jenna Congdon, asks a different and arguably more uncomfortable question. As longevity medicine grows into a genuine industry, who actually gets access to it, and what happens to health inequity if the answer stays "mostly the wealthy"?

We don't just want to live longer, we want to live better

One detail from the article is worth sitting with before anything else. In a survey of a thousand people in the US, nearly eighty percent said they would want to live to 120, but only under one condition: that they remained mentally and physically healthy. Remove that guarantee, and most people's enthusiasm dropped sharply.

This distinction matters enormously for how we think about longevity. The goal was never simply more years. It is more healthy years, which is precisely the philosophy behind what the article calls longevity medicine: a prevention-focused, highly personalized approach to healthcare built around catching and managing age-related decline early, using tools like genomic testing, biomarker tracking, and AI-driven analysis, rather than waiting for disease to appear and reacting afterward.

The problem: this kind of medicine is expensive, and expertise is unevenly distributed

Right now, this proactive approach is largely delivered through concierge clinics operating outside standard insurance-based care, accessible mainly to those who can pay out of pocket. Congdon's reporting draws on the work of Jordan Weiss, an aging and health equity researcher at NYU Grossman School of Medicine, who frames the issue with a pointed thought experiment: people are often excited about the idea of living to 150, until you add the condition of doing so in poor health and without enough money to cover basic needs. At that point, most people's interest evaporates, which is really the crux of the whole equity concern.

Weiss also raises a subtler barrier beyond simple affordability: interpretation. Longevity medicine tends to generate an enormous amount of personal health data, genetic risk profiles, biomarker panels, predictive models, and all of that information is only useful if someone can actually understand and act on it. That requires a level of health literacy that tends to correlate with education and income. In Weiss's framing, wealthier patients walking into longevity clinics are not just paying for the intervention itself, they are effectively paying for someone to do the cognitive work of interpreting and navigating that information for them, a layer of support largely absent from standard primary care.

Because income is such a powerful driver of health outcomes to begin with, the article cites research showing a striking gap in life expectancy tied to earnings: a difference of more than fourteen years between the top and bottom one percent of male earners in the US, and roughly a ten-year gap for women. Layering an expensive, highly personalized longevity approach on top of that existing disparity risks widening it further rather than closing it.

Why this could quietly deepen inequality over time

The article raises a particularly important point about how these effects compound. Because longevity interventions tend to be preventive and cumulative, meaning their benefit builds gradually over years and decades rather than appearing immediately, unequal access does not just create a one-time gap. It can create a slowly widening divergence in healthspan between those who can access this kind of proactive care and those who cannot, one that becomes more pronounced the longer it continues.

There is also a more subtle equity issue buried in how people relate to their own health. Chronic disease tends to be more prevalent in socioeconomically disadvantaged populations, which can quietly reshape what "feeling healthy" even means to someone. If chronic illness has always been a common backdrop, a person may be less likely to interpret early symptoms as worth investigating, potentially delaying care that could meaningfully affect their health over decades. This is a very different starting point than the mindset longevity medicine tends to assume: an engaged, informed patient consistently optimizing for future health.

What a more ethical path might look like

The article does not end on a purely cautionary note. It outlines several concrete directions for making this field more equitable as it grows:

• Research that includes diverse populations, so interventions are actually studied and validated within the context of different socioeconomic communities, not just affluent ones
  

• Equity-conscious pricing from companies developing these tools, paired with honest, non-exaggerated marketing about what current evidence does and does not support
  

• Stronger policy and regulation ensuring pricing transparency and broader access, rather than leaving distribution purely to market forces
  

• Integration into public health systems, rather than keeping longevity medicine siloed within private, concierge-style care
  

There is also a genuinely thoughtful point about the emotional weight of this kind of data. Weiss raises the example of learning you carry a genetic predisposition to a condition with no current cure, such as Alzheimer's disease. More information is not automatically more helpful; it can also be more distressing, without a clear next step attached to it. Part of the clinician's role, in this framing, is not just delivering data but helping a person understand what to actually do with it, and what can reasonably be set aside.

Why this belongs in the longevity conversation

It would be easy to treat longevity science as a purely personal pursuit, something each of us can optimize individually with the right knowledge and enough discipline. This article is a useful check on that framing. The tools of longevity medicine are only as meaningful as who can actually reach them, and the growing sophistication of this field will mean very little for population-level health if its benefits stay concentrated among people who already have the most resources and the best starting point.

The honest version of this conversation holds both things at once: genuine excitement about what personalized, preventive medicine can offer, and a clear-eyed acknowledgment that without deliberate effort, this next frontier in medicine could end up deepening the very inequities it has the potential to help address.

Source: Congdon J. "The Ethics of Extending Life: Longevity Medicine and Health Inequity." J Med Internet Res. 2026;28:e104414. PMID: 42320037.